Transcode Therapeutics Inc (RNAZ)
$0.26
Performance
- $0.25$0.26$0.26
3.46%
Downside
Day's Volatility :3.46%
Upside
0.0%
- $0.22$128.00$0.26
16.92%
Downside
52 Weeks Volatility :99.83%
Upside
99.8%
Returns
| Period | Transcode Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -79.53% | 0.0% |
6 Months | -58.66% | 0.0% |
1 Year | -99.27% | 0.0% |
3 Years | -99.99% | -20.6% |
Highlights
Market Capitalization | 4.6M |
Book Value | $0.18 |
Earnings Per Share (EPS) | 268.14 |
PE Ratio | 0.0 |
Wall Street Target Price | 120.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -207.95% |
Return On Equity TTM | -1048.7% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -17.7M |
Diluted Eps TTM | 268.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.05 |
EPS Estimate Next Year | -0.6 |
EPS Estimate Current Quarter | -0.58 |
EPS Estimate Next Quarter | -0.35 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 46053.85%
Technicals Summary
Sell
Neutral
Buy
Transcode Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Transcode Therapeutics Inc | 0.04% | -58.66% | -99.27% | -99.99% | -99.99% |
 Regeneron Pharmaceuticals, Inc. | 0.93% | 17.32% | 35.75% | 73.95% | 298.81% |
 Novo Nordisk A/s | 0.96% | -0.08% | 31.44% | 163.47% | 428.79% |
 Alnylam Pharmaceuticals, Inc. | -8.66% | 65.51% | 21.14% | 30.19% | 192.84% |
 Vertex Pharmaceuticals Incorporated | 0.75% | 12.92% | 34.78% | 148.18% | 173.67% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Transcode Therapeutics Inc | 0.0 | 0.0 | NA | -2.05 | -10.49 | -2.08 | NA | 0.18 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Transcode Therapeutics Inc | Buy | $4.6M | -99.99% | 0.0 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 298.81% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 428.79% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 192.84% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 173.67% | 32.84 | -4.74% |
Insights on Transcode Therapeutics Inc
Vs VRTX
In the last 1 year, Vertex Pharmaceuticals Incorporated has given 36.4% return, outperforming this stock by 135.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 148.2% return, outperforming this stock by 248.2%
Institutional Holdings
Virtu Financial LLC
0.32%Sheets Smith Wealth Management
0.12%PRIVATE CAPITAL MANAGEMENT LLC
0.10%Ronna Sue Cohen
0.10%TWO SIGMA SECURITIES, LLC
0.07%CapTrust Financial Advisors
0.07%
Company Information
transcode therapeutics is a boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microrna (mirnas or mirs) therapeutics for treating metastatic disease.
Organization | Transcode Therapeutics Inc |
Employees | 10 |
CEO | Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$0.26
+0.33%
Keyarch Acquisition Corp
$0.26
+0.33%
Connexa Sports Technologies Inc
$0.26
+0.33%
Us Value Etf
$0.26
+0.33%
First Wave Biopharma Inc
$0.26
+0.33%
Global X Msci Next Emerging
$0.26
+0.33%
Fat Projects Acquisition Corp
$0.26
+0.33%
Capital Link Global Fintech
$0.26
+0.33%
Applied Uv Inc
$0.26
+0.33%